Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer
Molecular target therapy is one of the most popular field of non-small cell lung cancer (NSCLC) treatmnet. Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearragement are the most important two oncogenic drivers in NSCLC, early studies suggested that EGFR mutat...
Main Authors: | , |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2018-09-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2018.09.07 |
id |
doaj-a5106af485814b54b7d7d1fd42724e2c |
---|---|
record_format |
Article |
spelling |
doaj-a5106af485814b54b7d7d1fd42724e2c2020-11-25T01:41:00ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872018-09-0121968669110.3779/j.issn.1009-3419.2018.09.07Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung CancerXin WANG0Diansheng ZHONG1Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, ChinaDepartment of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, ChinaMolecular target therapy is one of the most popular field of non-small cell lung cancer (NSCLC) treatmnet. Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearragement are the most important two oncogenic drivers in NSCLC, early studies suggested that EGFR mutations and ALK rearrangements are mutually exclusive, but isolated cases or small sample research with concomitant EGFR and ALK alterations have been constantly reported. The co-occurrence of EGFR mutations and anaplastic lymphoma kinase (ALK) rearrangements constitutes a rare molecular, the frequency of EGFR/ALK co-alterations was about 1%, however, little has been known about clinicopathologic feature and treatment. This review summarized published case report, EGFR and ALK alterations are common in female, Asian origin, never smoker, IV stage, and denocarcinomas. First-line treatment can choose EGFR or ALK tyrosine kinase inhibitors (TKIs). However, studies about the origin and resistance mechanism in EGFR/ALK co-alterations are little, require more experimental and clinical research.http://dx.doi.org/10.3779/j.issn.1009-3419.2018.09.07Lung neoplasmsEpidermal growth factor receptor (EGFR)Anaplastic lymphoma kinase (ALK) |
collection |
DOAJ |
language |
zho |
format |
Article |
sources |
DOAJ |
author |
Xin WANG Diansheng ZHONG |
spellingShingle |
Xin WANG Diansheng ZHONG Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer Chinese Journal of Lung Cancer Lung neoplasms Epidermal growth factor receptor (EGFR) Anaplastic lymphoma kinase (ALK) |
author_facet |
Xin WANG Diansheng ZHONG |
author_sort |
Xin WANG |
title |
Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer |
title_short |
Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer |
title_full |
Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer |
title_fullStr |
Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer |
title_full_unstemmed |
Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer |
title_sort |
advances in double mutations of egfr and alk gene in non-small cell lung cancer |
publisher |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
series |
Chinese Journal of Lung Cancer |
issn |
1009-3419 1999-6187 |
publishDate |
2018-09-01 |
description |
Molecular target therapy is one of the most popular field of non-small cell lung cancer (NSCLC) treatmnet. Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearragement are the most important two oncogenic drivers in NSCLC, early studies suggested that EGFR mutations and ALK rearrangements are mutually exclusive, but isolated cases or small sample research with concomitant EGFR and ALK alterations have been constantly reported. The co-occurrence of EGFR mutations and anaplastic lymphoma kinase (ALK) rearrangements constitutes a rare molecular, the frequency of EGFR/ALK co-alterations was about 1%, however, little has been known about clinicopathologic feature and treatment. This review summarized published case report, EGFR and ALK alterations are common in female, Asian origin, never smoker, IV stage, and denocarcinomas. First-line treatment can choose EGFR or ALK tyrosine kinase inhibitors (TKIs). However, studies about the origin and resistance mechanism in EGFR/ALK co-alterations are little, require more experimental and clinical research. |
topic |
Lung neoplasms Epidermal growth factor receptor (EGFR) Anaplastic lymphoma kinase (ALK) |
url |
http://dx.doi.org/10.3779/j.issn.1009-3419.2018.09.07 |
work_keys_str_mv |
AT xinwang advancesindoublemutationsofegfrandalkgeneinnonsmallcelllungcancer AT dianshengzhong advancesindoublemutationsofegfrandalkgeneinnonsmallcelllungcancer |
_version_ |
1725043133461299200 |